Genomind
King of Prussia, US · Delaware corporation · 2 known investors
Genomind provides pharmacogenetic testing and precision medicine software to help healthcare providers tailor medication prescriptions based on patients' genetic profiles, lifestyle, and environment. The platform integrates genetic data with clinical expertise to reduce adverse drug events and improve treatment outcomes across individual and population health settings.
Founders & leadership
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$55.7M disclosed across 4 rounds · 2014–2020
▶$6.4MraisedApr 2021 · 8 investors · Other Health CareRule 506(b)
- Beth DozoretzDirector
- Tom HessExecutive Officer
- Shelloy KigerDirector
- Stephen HallerExecutive Officer
- Theresa SextonDirector
- John ChadwickDirector
- Shawn Patrick O'BrienExecutive Officer, Director
- Offering amount
- $21.1M
- Amount sold
- $6.4M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.6MraisedSep 2020 · 2 investors · Other Health CareRule 506(b)
- Stephen HallerExecutive Officer
- Thomas HessExecutive Officer
- Gloria NussExecutive Officer
- Kip OlmsteadExecutive Officer
- Brad LucasDirector
- Shawn P. O'BrienExecutive Officer, Director
- Theresa SextonDirector
- John ChadwickDirector
- Joseph AntonDirector
- Offering amount
- $21.7M
- Amount sold
- $20.6M
- Minimum investment
- $100K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedOct 2017 · 5 investors · Other Health CareRule 506(b)
- Theresa SextonDirector
- Beth E. DozoretzExecutive Officer, Director
- Joseph AntonDirector
- Ronald I. DozoretzExecutive Officer, Director, Promoter
- Thomas HessExecutive Officer
- Stephen HallerExecutive Officer
- Rina WolfDirector
- Gloria NussExecutive Officer
- John ChadwickDirector
- Michael KofflerExecutive Officer, Director, Promoter
- Offering amount
- $13.8M
- Amount sold
- $7.8M
- Minimum investment
- $250K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$20.9MraisedJul 2016 · 6 investors · Other Health CareRule 506(b)
- Stephen HallerExecutive Officer
- Rina WolfDirector
- Ronald I. DozoretzExecutive Officer, Director, Promoter
- Michael KofflerExecutive Officer, Director, Promoter
- Gloria NussExecutive Officer
- Beth E. DozoretzExecutive Officer, Director
- John ChadwickDirector
- Theresa SextonDirector
- Joseph AntonDirector
- Thomas HessExecutive Officer
- Offering amount
- $25.9M
- Amount sold
- $20.9M
- Minimum investment
- $200K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Genomind for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $399.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Genomind do?
- Genomind provides pharmacogenetic testing and precision medicine software to help healthcare providers tailor medication prescriptions based on patients' genetic profiles, lifestyle, and environment. The platform integrates genetic data with clinical expertise to reduce adverse drug events and improve treatment outcomes across individual and population health settings.
- Who are Genomind's investors?
- Genomind's investors include Claritas Capital, Claritas Healthcare.
- How much funding has Genomind raised?
- Genomind has disclosed $55.7M raised across 4 rounds.
- Where is Genomind headquartered?
- Genomind is headquartered in King of Prussia, US.